Metabolism and Nutrition Research Group, Louvain Drug Research Institute, UCLouvain, Université catholique de Louvain, avenue E. Mounier box B1.73.11, B-1200, Brussels, Belgium.
Department of Medicine, University of Alberta, Edmonton, Canada.
Eur J Nutr. 2021 Sep;60(6):3159-3170. doi: 10.1007/s00394-021-02484-5. Epub 2021 Feb 5.
Inulin-type fructans (ITF) are prebiotic dietary fibre (DF) that may confer beneficial health effects, by interacting with the gut microbiota. We have tested the hypothesis that a dietary intervention promoting inulin intake versus placebo influences fecal microbial-derived metabolites and markers related to gut integrity and inflammation in obese patients.
Microbiota (16S rRNA sequencing), long- and short-chain fatty acids (LCFA, SCFA), bile acids, zonulin, and calprotectin were analyzed in fecal samples obtained from obese patients included in a randomized, placebo-controlled trial. Participants received either 16 g/d native inulin (prebiotic n = 12) versus maltodextrin (placebo n = 12), coupled to dietary advice to consume inulin-rich versus inulin-poor vegetables for 3 months, in addition to dietary caloric restriction.
Both placebo and prebiotic interventions lowered energy and protein intake. A substantial increase in Bifidobacterium was detected after ITF treatment (q = 0.049) supporting our recent data obtained in a larger cohort. Interestingly, fecal calprotectin, a marker of gut inflammation, was reduced upon ITF treatment. Both prebiotic and placebo interventions increased the ratio of tauro-conjugated/free bile acids in feces. Prebiotic treatment did not significantly modify fecal SCFA content but it increased fecal rumenic acid, a conjugated linoleic acid (cis-9, trans-11 CLA) with immunomodulatory properties, that correlated notably to the expansion of Bifidobacterium (p = 0.031; r = 0.052).
Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. CLINICALTRIALS.
NCT03852069 (February 22, 2019 retrospectively, registered).
菊粉型果聚糖(ITF)是一种益生元膳食纤维(DF),通过与肠道微生物群相互作用,可能对健康产生有益影响。我们已经验证了这样一种假设,即促进菊粉摄入的饮食干预与安慰剂相比,会影响肥胖患者粪便微生物衍生代谢物和与肠道完整性及炎症相关的标志物。
从参与随机、安慰剂对照试验的肥胖患者的粪便样本中分析了微生物群(16S rRNA 测序)、长链和短链脂肪酸(LCFA、SCFA)、胆汁酸、肠紧密连接蛋白和钙卫蛋白。参与者接受 16 g/d 天然菊粉(益生元组 n=12)或麦芽糊精(安慰剂组 n=12)干预,同时辅以富含或缺乏菊粉的蔬菜饮食建议,以及饮食热量限制,共 3 个月。
安慰剂和益生元干预均降低了能量和蛋白质的摄入。在 ITF 治疗后,检测到双歧杆菌的数量显著增加(q=0.049),这支持了我们最近在更大队列中获得的数据。有趣的是,粪便钙卫蛋白(一种肠道炎症的标志物)在 ITF 治疗后降低。益生元和安慰剂干预均增加粪便中牛磺酸结合/游离胆汁酸的比值。益生元治疗并未显著改变粪便短链脂肪酸含量,但增加了粪便里亚油酸(一种具有免疫调节特性的共轭亚油酸(cis-9,trans-11 CLA))的含量,双歧杆菌的扩张与亚油酸的增加显著相关(p=0.031;r=0.052)。
我们的研究表明,在 3 个月的时间内摄入 ITF 益生元可降低肥胖患者粪便中肠道炎症的标志物。我们的数据表明,微生物脂质衍生代谢物可能与肥胖相关的胃肠功能障碍有关。临床试验。
GOV 标识符:NCT03852069(2019 年 2 月 22 日,追溯注册)。